Bilaketaren emaitzak - Dafna D Gladman

Findu emaitzak
  1. 1
    Psoriatic arthritis

    Psoriatic arthritis nork Dafna D. Gladman

    Argitaratua 2009
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Atherosclerosis in psoriatic disease: latest evidence and clinical implications

    Atherosclerosis in psoriatic disease: latest evidence and clinical implications nork Lihi Eder, Dafna D. Gladman

    Argitaratua 2015
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program

    Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program nork Dafna D. Gladman, Vimal Chandran

    Argitaratua 2010
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments

    Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments nork Zahi Touma, Dafna D. Gladman

    Argitaratua 2017
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Venous syndromes and pulmonary embolism in systemic lupus erythematosus.

    Venous syndromes and pulmonary embolism in systemic lupus erythematosus. nork Dafna D. Gladman, Murray B. Urowitz

    Argitaratua 1980
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Psoriatic arthritis

    Psoriatic arthritis nork Vanessa Ocampo D, Dafna D. Gladman

    Argitaratua 2019
    Testu osoa Testu osoa
    Pré-impressão
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Psoriatic spondyloarthropathy: a long term prospective study.

    Psoriatic spondyloarthropathy: a long term prospective study. nork John G. Hanly, Michelle Russell, Dafna D. Gladman

    Argitaratua 1988
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies

    Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies nork Konstantinos Tselios, Dafna D. Gladman, Murray B. Urowitz

    Argitaratua 2016
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Treatment guidelines in psoriatic arthritis

    Treatment guidelines in psoriatic arthritis nork Alexis Ogdie, Laura C. Coates, Dafna D. Gladman

    Argitaratua 2019
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Dactylitis in Psoriatic Arthritis: Prevalence and Response to Therapy in the Biologic Era

    Dactylitis in Psoriatic Arthritis: Prevalence and Response to Therapy in the Biologic Era nork Dafna D. Gladman, Olga Ziouzina, Arane Thavaneswaran, Vinod Chandran

    Argitaratua 2013
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  11. 11
    Predictors for radiological damage in psoriatic arthritis: results from a single centre

    Predictors for radiological damage in psoriatic arthritis: results from a single centre nork Simon Bond, Vernon T. Farewell, Catherine T. Schentag, Dafna D. Gladman

    Argitaratua 2006
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    Excessive paternal transmission in psoriatic arthritis

    Excessive paternal transmission in psoriatic arthritis nork Proton Rahman, Dafna D. Gladman, Catherine T. Schentag, Artūras Petronis

    Argitaratua 1999
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  13. 13
    Responses to Adalimumab in Patients with Active Psoriatic Arthritis Who Have Not Adequately Responded to Prior Therapy: Effectiveness and Safety Results From an Open-label Study

    Responses to Adalimumab in Patients with Active Psoriatic Arthritis Who Have Not Adequately Responded to Prior Therapy: Effectiveness and Safety Results From an Open-label Study nork Dafna D. Gladman, John S. Sampalis, OLIVIER ILLOUZ, B. Guérette

    Argitaratua 2010
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  14. 14
    Functional Assessment of Chronic Illness Therapy-Fatigue Scale is valid in patients with psoriatic arthritis

    Functional Assessment of Chronic Illness Therapy-Fatigue Scale is valid in patients with psoriatic arthritis nork V. Chandran, Sita Bhella, Catherine T. Schentag, Dafna D. Gladman

    Argitaratua 2007
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  15. 15
    Incremental Effects of Comorbidity on Quality of Life in Patients with Psoriatic Arthritis

    Incremental Effects of Comorbidity on Quality of Life in Patients with Psoriatic Arthritis nork Janice Husted, Arane Thavaneswaran, Vinod Chandran, Dafna D. Gladman

    Argitaratua 2013
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  16. 16
    Development and Initial Validation of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50

    Development and Initial Validation of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50 nork Zahi Touma, Dafna D. Gladman, Dominique Ibañez, Murray B. Urowitz

    Argitaratua 2010
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  17. 17
    Prolonged Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Frequency and Outcome

    Prolonged Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Frequency and Outcome nork Amanda Steiman, Dafna D. Gladman, Dominique Ibañez, Murray B. Urowitz

    Argitaratua 2010
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  18. 18
    Psoriatic arthritis assessment tools in clinical trials

    Psoriatic arthritis assessment tools in clinical trials nork Philip J. Mease, Christian Antoni, Dafna D. Gladman, W Taylor

    Argitaratua 2005
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  19. 19
    Is There an Advantage Over SF-36 with a Quality of Life Measure That Is Specific to Systemic Lupus Erythematosus?

    Is There an Advantage Over SF-36 with a Quality of Life Measure That Is Specific to Systemic Lupus Erythematosus? nork Zahi Touma, Dafna D. Gladman, Dominique Ibañez, Murray B. Urowitz

    Argitaratua 2011
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  20. 20
    Risk Factors for Axial Inflammatory Arthritis in Patients with Psoriatic Arthritis

    Risk Factors for Axial Inflammatory Arthritis in Patients with Psoriatic Arthritis nork Vinod Chandran, David Tolusso, Richard J. Cook, Dafna D. Gladman

    Argitaratua 2010
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: